Dabigatran etexilate

Dabigatran etexilate Reactions 1680, p109 - 2 Dec 2017 Interstitial pneumonia: case report A 73-year-old man developed interstitial pneumonia during treatment with dabigatran etexilate [dabigatran; dosage, route and time to reaction onset not stated]. The man, who had a history of paroxysmal atrial fibrillation and chronic heart failure, had been receiving anticoagulant therapy with dabigatran etexilate for 24 months. He presented with dry cough and exertional dyspnoea. On respiratory system examination, he showed fine crackles at lower back. Chest X-ray revealed lower field bilateral infiltration. Chest CT scan demonstrated ground glass opacity and non-segmental subpleural consolidation, which was consistent with nonspecific interstitial pneumonia (NSIP) with organising pneumonia (OP) pattern. He showed increased levels of KL-6, neutrophil and eosinophil without anaemia as well as autoantibodies. The man’s dabigatran etexilate therapy was discontinued, and bronchoscopy was done to check progress in his condition. Bronchoalveolar lavage fluid (BALF) was not bloody. He showed reduction in eosinophil and neutrophil levels. He also showed lymphocytes of 17.7% and CD4/CD8 ratio of 1.81 in BALF with no signs of infection. Trans-bronchial lung biopsy specimen demonstrated OP. His therapy was then switched to warfarin from dabigatran etexilate. Two months after the initiation of warfarin therapy, X-ray and Chest CT scan findings showed improvement of the previously existing opacities. Six months later, KL-6 levels returned to normal. Based on these findings, a diagnosis of dabigatran etexilate-induced interstitial pneumonia was made. Author comment: "Drug-induced lung injury is diagnosed on the basis of clinical examination and radiographic and histological findings". "Cases that develop subacutely, as in the present case, tend to be [nonspecific interstitial pneumonia] or [organising pneumonia]." "Therefore, the patient’s interstitial pneumonia was diagnosed to be a drug- induced lung injury caused by dabigatran." Yanagihara T, et al. Interstitial pneumonia caused by dabigatran. Respiratory Medicine Case Reports 23: 10-12, Jan 2018. Available from: URL: http:// doi.org/10.1016/j.rmcr.2017.10.009 - Japan 803284578 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Dabigatran etexilate

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/dabigatran-etexilate-Pz87W0PkWM
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39040-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p109 - 2 Dec 2017 Interstitial pneumonia: case report A 73-year-old man developed interstitial pneumonia during treatment with dabigatran etexilate [dabigatran; dosage, route and time to reaction onset not stated]. The man, who had a history of paroxysmal atrial fibrillation and chronic heart failure, had been receiving anticoagulant therapy with dabigatran etexilate for 24 months. He presented with dry cough and exertional dyspnoea. On respiratory system examination, he showed fine crackles at lower back. Chest X-ray revealed lower field bilateral infiltration. Chest CT scan demonstrated ground glass opacity and non-segmental subpleural consolidation, which was consistent with nonspecific interstitial pneumonia (NSIP) with organising pneumonia (OP) pattern. He showed increased levels of KL-6, neutrophil and eosinophil without anaemia as well as autoantibodies. The man’s dabigatran etexilate therapy was discontinued, and bronchoscopy was done to check progress in his condition. Bronchoalveolar lavage fluid (BALF) was not bloody. He showed reduction in eosinophil and neutrophil levels. He also showed lymphocytes of 17.7% and CD4/CD8 ratio of 1.81 in BALF with no signs of infection. Trans-bronchial lung biopsy specimen demonstrated OP. His therapy was then switched to warfarin from dabigatran etexilate. Two months after the initiation of warfarin therapy, X-ray and Chest CT scan findings showed improvement of the previously existing opacities. Six months later, KL-6 levels returned to normal. Based on these findings, a diagnosis of dabigatran etexilate-induced interstitial pneumonia was made. Author comment: "Drug-induced lung injury is diagnosed on the basis of clinical examination and radiographic and histological findings". "Cases that develop subacutely, as in the present case, tend to be [nonspecific interstitial pneumonia] or [organising pneumonia]." "Therefore, the patient’s interstitial pneumonia was diagnosed to be a drug- induced lung injury caused by dabigatran." Yanagihara T, et al. Interstitial pneumonia caused by dabigatran. Respiratory Medicine Case Reports 23: 10-12, Jan 2018. Available from: URL: http:// doi.org/10.1016/j.rmcr.2017.10.009 - Japan 803284578 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off